JP2017505822A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505822A5
JP2017505822A5 JP2016569114A JP2016569114A JP2017505822A5 JP 2017505822 A5 JP2017505822 A5 JP 2017505822A5 JP 2016569114 A JP2016569114 A JP 2016569114A JP 2016569114 A JP2016569114 A JP 2016569114A JP 2017505822 A5 JP2017505822 A5 JP 2017505822A5
Authority
JP
Japan
Prior art keywords
group
psoriasis
pharmaceutically acceptable
complex according
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569114A
Other languages
English (en)
Japanese (ja)
Other versions
JP6445591B2 (ja
JP2017505822A (ja
Filing date
Publication date
Priority claimed from HU1400075A external-priority patent/HUP1400075A2/hu
Application filed filed Critical
Publication of JP2017505822A publication Critical patent/JP2017505822A/ja
Publication of JP2017505822A5 publication Critical patent/JP2017505822A5/ja
Application granted granted Critical
Publication of JP6445591B2 publication Critical patent/JP6445591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569114A 2014-02-14 2015-02-13 シロリムス及びその誘導体の複合体、それらの調製方法ならびにそれらを含有する医薬組成物 Expired - Fee Related JP6445591B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1400075A HUP1400075A2 (hu) 2014-02-14 2014-02-14 Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
HUP1400075 2014-02-14
PCT/IB2015/051086 WO2015121836A1 (en) 2014-02-14 2015-02-13 Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Publications (3)

Publication Number Publication Date
JP2017505822A JP2017505822A (ja) 2017-02-23
JP2017505822A5 true JP2017505822A5 (cg-RX-API-DMAC7.html) 2018-04-05
JP6445591B2 JP6445591B2 (ja) 2018-12-26

Family

ID=89991398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016569114A Expired - Fee Related JP6445591B2 (ja) 2014-02-14 2015-02-13 シロリムス及びその誘導体の複合体、それらの調製方法ならびにそれらを含有する医薬組成物

Country Status (14)

Country Link
US (1) US20170165237A1 (cg-RX-API-DMAC7.html)
EP (1) EP3104844B1 (cg-RX-API-DMAC7.html)
JP (1) JP6445591B2 (cg-RX-API-DMAC7.html)
CN (1) CN106456780A (cg-RX-API-DMAC7.html)
AU (1) AU2015216631B2 (cg-RX-API-DMAC7.html)
CA (1) CA2939602A1 (cg-RX-API-DMAC7.html)
ES (1) ES2784843T3 (cg-RX-API-DMAC7.html)
HK (1) HK1231416A1 (cg-RX-API-DMAC7.html)
HU (2) HUP1400075A2 (cg-RX-API-DMAC7.html)
IL (1) IL247239A0 (cg-RX-API-DMAC7.html)
PL (1) PL3104844T3 (cg-RX-API-DMAC7.html)
RU (1) RU2016136697A (cg-RX-API-DMAC7.html)
UA (1) UA120508C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015121836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
US10376501B2 (en) 2016-04-25 2019-08-13 Druggability Technologies Ip Holdco Limited Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
HUP1600269A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
HUP1600271A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
BR112019002689A2 (pt) * 2016-08-10 2019-05-14 Univ Texas terapia com rapamicina tópica
IL302385B2 (en) * 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
JP7376361B2 (ja) * 2017-03-07 2023-11-08 エフ． ホフマン－ラ ロシュ アーゲー 免疫調節マクロライドのための安定な配合物
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
MX2021010058A (es) * 2019-02-20 2021-11-12 Ai Therapeutics Inc Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5154684A (en) 1989-06-05 1992-10-13 Delf Eric W Exercise apparatus for the human body
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
ZA935110B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CA2230748C (en) 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0126253D0 (en) 2001-10-31 2002-01-02 Metris Therapeutics Ltd Treatment method
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
AR045957A1 (es) 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations
BRPI0608573A2 (pt) * 2005-03-08 2017-07-25 Lifecycle Pharma As Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
CA2601312A1 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
CA2603987A1 (en) 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
WO2006123226A2 (en) 2005-05-18 2006-11-23 De Villiers, Malan An inhibitor of mtor for inhibiting the formation of scar tissue
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
BRPI0600285C1 (pt) 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
GB0602632D0 (en) 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
CN1919194A (zh) 2006-08-17 2007-02-28 刘瑜玲 西罗莫司的液体组合物
US20080138405A1 (en) 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
MX380318B (es) 2007-03-07 2025-03-12 Abraxis Bioscience Llc Nanoparticula que comprende rapamicina y albumina como agente anticancer.
US20090130210A1 (en) 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
US20090068266A1 (en) 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
US20100098770A1 (en) 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
HUP0900384A2 (en) 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
HUP0900376A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
US20120135053A1 (en) 2009-06-19 2012-05-31 Filipcsei Genoveva Nanoparticulate telmisartan compositions and process for the preparation thereof
JP5947717B2 (ja) 2009-06-19 2016-07-06 ナノフォーム ハンガリー リミテッド ナノ構造のシルデナフィル塩基、薬学的に許容されるその塩及び共結晶、それらの組成物、その調製方法、並びにそれらを含有する医薬組成物
KR101721281B1 (ko) 2009-09-25 2017-04-10 위스콘신 얼럼나이 리서어치 화운데이션 치료제의 미셀 캡슐화
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
WO2011128910A2 (en) 2010-03-02 2011-10-20 Rpg Life Sciences Limited A drug delivery solid dosage formulation of sirolimus
WO2011135580A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
EP2575889B1 (en) 2010-06-02 2015-04-22 Fresenius Kabi Oncology Ltd Stable pharmaceutical compositions of rapamycin esters
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
IT1400977B1 (it) 2010-07-01 2013-07-05 Euticals Spa Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
US20130102572A1 (en) 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
WO2013022201A1 (en) 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
KR101151890B1 (ko) 2011-08-11 2012-05-31 동아제약주식회사 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition

Similar Documents

Publication Publication Date Title
JP2017505822A5 (cg-RX-API-DMAC7.html)
JP2016535777A5 (cg-RX-API-DMAC7.html)
RU2016136697A (ru) Комплексы сиролимуса и его производных, способ их получения и фармацевтические композиции, содержащие указанные комплексы
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
CN106232144B (zh) 固体分散体
JP2015511241A5 (cg-RX-API-DMAC7.html)
WO2012116238A1 (en) PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
JP2018504443A5 (cg-RX-API-DMAC7.html)
RU2013122656A (ru) Композиции и способы доставки терапевтических средств
CN101631533B (zh) 含有西洛他唑的控释制剂及其制备方法
TW201444589A (zh) 錠劑型式
JP2017526697A5 (cg-RX-API-DMAC7.html)
JP2017527600A5 (cg-RX-API-DMAC7.html)
JP2017531044A5 (cg-RX-API-DMAC7.html)
Tran et al. Modulation of drug crystallization and molecular interactions by additives in solid dispersions for improving drug bioavailability
US20170368031A1 (en) Solid dispersion formulations of antiviral compounds
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
CN102548543B (zh) 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂
JP2015520241A5 (cg-RX-API-DMAC7.html)
JP6843896B2 (ja) 水性点眼点鼻用組成物
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
TW202237145A (zh) 莫奈皮拉韋的醫藥組成物
US20160346289A1 (en) Fixed-Dose Combinations of Antiviral Compounds
JP2018123140A (ja) 活性成分（ｉ）含有組成物及びその製造方法
CN118414146A (zh) 包含丙酚替诺福韦和/或比克替拉韦的固体组合物